Histotripsy using very short monopolar ultrasound pulses

Information

  • Patent Grant
  • 10780298
  • Patent Number
    10,780,298
  • Date Filed
    Friday, August 22, 2014
    10 years ago
  • Date Issued
    Tuesday, September 22, 2020
    4 years ago
Abstract
Apparatus and methods are provided for applying ultrasound pulses into tissue or a medium in which the peak negative pressure (P−) of one or more negative half cycle(s) of the ultrasound pulses exceed(s) an intrinsic threshold of the tissue or medium, to directly form a dense bubble cloud in the tissue or medium without shock-scattering. In one embodiment, a microtripsy method of Histotripsy therapy comprises delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds an intrinsic threshold in the tissue to produce a bubble cloud of at least one bubble in the tissue, and generating a lesion in the tissue with the bubble cloud. The intrinsic threshold can vary depending on the type of tissue to be treated. In some embodiments, the intrinsic threshold in tissue can range from 15-30 MPa.
Description
INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


FIELD

This disclosure generally relates to treating tissue with bubble clouds created by ultrasound therapy.


BACKGROUND

Histotripsy, or pulsed ultrasound cavitation therapy, is a technology where extremely short, intense bursts of acoustic energy induce controlled cavitation (microbubble formation) within the focal volume. The vigorous expansion and collapse of these microbubbles mechanically homogenizes cells and tissue structures within the focal volume. This is a very different end result than the coagulative necrosis characteristic of thermal ablation. To operate within a non-thermal, Histotripsy realm; it is necessary to deliver acoustic energy in the form of high amplitude acoustic pulses with low duty cycle.


Compared with conventional focused ultrasound technologies, Histotripsy has important advantages: 1) the destructive process at the focus is mechanical, not thermal; 2) bubble clouds appear bright on ultrasound imaging thereby confirming correct targeting and localization of treatment; 3) treated tissue appears darker (hypoechoic) on ultrasound imaging, so that the operator knows what has been treated; and 4) Histotripsy produces lesions in a controlled and precise manner. It is important to emphasize that unlike microwave, radiofrequency, or high-intensity focused ultrasound (HIFU), Histotripsy is not a thermal modality.


Histotripsy produces tissue fractionation through dense energetic bubble clouds generated by short, high-pressure, ultrasound pulses. Conventional Histotripsy treatments have used longer pulses from 3 to 10 cycles wherein the lesion-producing bubble cloud generation depends on the pressure-release scattering of very high peak positive shock fronts from previously initiated, sparsely distributed bubbles (the “shock-scattering” mechanism).


In conventional Histotripsy treatments, ultrasound pulses with ≥2 acoustic cycles are applied, and the bubble cloud formation relies on the pressure release scattering of the positive shock fronts (sometimes exceeding 100 MPa, P+) from initially initiated, sparsely distributed bubbles (or a single bubble). This has been called the “shock scattering mechanism”. This mechanism depends on one (or a few sparsely distributed) bubble(s) initiated with the initial negative half cycle(s) of the pulse at the focus of the transducer. A cloud of microbubbles then forms due to the pressure release backscattering of the high peak positive shock fronts from these sparsely initiated bubbles. These back-scattered high-amplitude rarefactional waves exceed the intrinsic threshold thus producing a localized dense bubble cloud. Each of the following acoustic cycles then induces further cavitation by the backscattering from the bubble cloud surface, which grows towards the transducer. As a result, an elongated dense bubble cloud growing along the acoustic axis opposite the ultrasound propagation direction is observed with the shock scattering mechanism. This shock scattering process makes the bubble cloud generation not only dependent on the peak negative pressure, but also the number of acoustic cycles and the amplitudes of the positive shocks. Without these intense shock fronts developed by nonlinear propagation, no dense bubble clouds are generated when the peak negative half-cycles are below the intrinsic threshold.


In more traditional ultrasound therapy, lesions are generated by forming an ultrasound beam into tight focal zones and using higher intensities within these foci to therapeutically modify tissue. Lesions are then generated either due to tissue heating (thermal therapy) or by mechanical agitation by energetic microbubble or bubble cloud formation (cavitation or Histotripsy). Minimum lesion size is typically determined by the diameter of the focal volume that, because of the limit due to diffraction, is around one wavelength of the propagating sound in the medium. A tightly focused ultrasound beam at 1 MHz (a typical therapeutic frequency) has a wavelength of about 1.5 mm in water or high water content tissue. Therefore, the focal diameter at 1 MHz is on the order of 1 mm or larger, depending on the transducer aperture. Using classical methods, getting smaller lesion diameters requires higher frequencies. Unfortunately, tissue penetration depth (due to increased tissue absorption and scattering) decreases with increasing frequency.


In the ultrasound cavitation based technology presented herein, much smaller diameters can be obtained at a given frequency where the lower limit in lesion size is the diameter of an individual microbubble, the primary effector in the process. Therefore, with proper pulse shaping and intensity, one can “beat” the “diffraction limit.”


SUMMARY OF THE DISCLOSURE

A method of treating tissue with ultrasound energy is provided, comprising the steps of delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds an intrinsic threshold in the tissue to produce a bubble cloud of at least one bubble in the tissue, and generating a lesion in the tissue with the bubble cloud.


In some embodiments, the ultrasound pulse comprises at least one half cycle.


In one embodiment, the intrinsic threshold is greater than or equal to 15 MPa peak negative pressure. In another embodiment, the intrinsic threshold is approximately 28 MPa peak negative pressure. In one embodiment, the intrinsic threshold is between approximately 26 MPa and 30 MPa peak negative pressure.


In some embodiments, the ultrasound pulse has a frequency between approximately 0.1 MHz and 20 MHz.


In one embodiment, the portion of the peak negative pressure half-cycle that exceeds the intrinsic threshold produces the bubble cloud while a remaining portion of the peak negative pressure half-cycle that does not exceed the intrinsic threshold does not produce the bubble cloud.


In another embodiment, the ultrasound pulse comprises a first ultrasound pulse, the method further comprising delivering a second ultrasound pulse having a smaller amplitude than the first ultrasound pulse, such that a portion of the peak negative pressure half-cycle of the second ultrasound pulse that exceeds the intrinsic threshold is smaller than the portion of the peak negative pressure half-cycle of the first ultrasound pulse that exceeds the intrinsic threshold.


In one embodiment, the second ultrasound pulse produces a smaller bubble cloud than the first ultrasound pulse.


In some embodiments, the ultrasound pulse comprises a first ultrasound pulse, the method further comprising delivering a second ultrasound pulse having a larger amplitude than the first ultrasound pulse, such that a portion of the peak negative pressure half-cycle of the second ultrasound pulse that exceeds the intrinsic threshold is larger than the portion of the peak negative pressure half-cycle of the first ultrasound pulse that exceeds the intrinsic threshold.


In one embodiment, the second ultrasound pulse produces a larger bubble cloud than the first ultrasound pulse.


In some embodiments, the bubble cloud is formed in the tissue without shock-scattering.


A method of treating tissue with ultrasound energy is provided, comprising the steps of delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds a peak negative pressure of 28 MPa in the tissue to produce a bubble cloud in the tissue, and generating a lesion in the tissue with the cavitation nuclei.


Another method of treating tissue with ultrasound energy is provided, comprising the steps of delivering a first ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds an intrinsic threshold in the tissue to produce a first bubble cloud in the tissue, and delivering a second ultrasound pulse having a different amplitude than the first ultrasound pulse from the ultrasound therapy transducer into tissue to produce a second bubble cloud in the tissue, such that a portion of the peak negative pressure half-cycle of the second ultrasound pulse that exceeds the intrinsic threshold is different than the portion of the peak negative pressure half-cycle of the first ultrasound pulse that exceeds the intrinsic threshold.


An ultrasound therapy system is provided, comprising an ultrasound therapy transducer, and an ultrasound therapy generator coupled to the ultrasound therapy transducer, the ultrasound therapy generator configured to drive the ultrasound therapy transducer to deliver an ultrasound pulse into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds an intrinsic threshold in the tissue to produce a bubble cloud in the tissue.


In some embodiments, the ultrasound therapy generator further comprises a controller configured to generate complex waveforms to initiate the ultrasound pulse, a high voltage power supply coupled to the controller, an amplifier configured to receive and amplify the complex waveforms from the controller and high voltage power supply, and a matching network configured to match an impedance of the ultrasound therapy transducer to the amplifier.


In some embodiments, the intrinsic threshold is greater than or equal to 15 MPa peak negative pressure. In other embodiments, the intrinsic threshold is approximately 28 MPa peak negative pressure. In another embodiment, the intrinsic threshold is between approximately 26 MPa and 30 MPa.


In some embodiments, the ultrasound pulse has a frequency between approximately 0.1 MHz and 20 MHz.


In another embodiment, the portion of the peak negative pressure half-cycle that exceeds the intrinsic threshold produces cavitation nuclei while a remaining portion of the peak negative pressure half-cycle that does not exceed the intrinsic threshold does not produce cavitation nuclei.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:



FIG. 1 shows one embodiment of a Histotripsy therapy system.



FIG. 2 illustrates an intrinsic threshold in tissue.



FIGS. 3A-3B show a beam profile and an intrinsic threshold in tissue.



FIGS. 4A-4B show a beam profile with an adjusted amplitude and an intrinsic threshold in tissue.



FIGS. 5A-5C illustrate the production of a bubble cloud in tissue in response to adjusting an amplitude of subsequent ultrasound pulses.





DETAILED DESCRIPTION

Histotripsy is a noninvasive, cavitation-based therapy that uses very short, high-pressure ultrasound pulses to generate a dense, energetic, lesion-producing bubble cloud. This Histotripsy treatment can create controlled tissue erosion when it is targeted at a fluid-tissue interface and well-demarcated tissue fractionation when it is targeted within bulk tissue. Additionally, Histotripsy has been shown to be capable of fragmenting model kidney stones using surface erosion that is mechanistically distinct from conventional shockwave lithotripsy (SWL). Histotripsy therapy can be guided and monitored using ultrasound B-mode imaging in real-time, since 1) the bubble cloud appears as a temporally changing hyperechoic region in B-mode imaging, allowing the treatment to be precisely targeted, and 2) the echogenicity of the targeted region decreases as the degree of tissue fractionation increases, which can be used as a way of monitoring lesion production (image feedback) in real-time.


In this disclosure, methods, procedures, materials, and devices that produce ultrasound cavitation lesions much smaller than the diffraction limit (the minimal size of a focal zone . . . usually around one wavelength of the incident ultrasound) are presented. The technology is based on generating an extremely consistent bubble cloud with the first peak negative half-cycle of every single or multi-cycle ultrasound pulse. This can be accomplished with an ultrasound transducer capable of generating in the target volume a peak negative pressure exceeding an intrinsic threshold (sometimes called the “homogeneous” or de novo threshold) for cavitation, i.e., the level whereby the whole volume above this peak-negative threshold generates an immediate bubble cloud throughout the supra-threshold volume. The resulting bubble cloud can generate a therapeutic lesion in the tissue. Below this threshold, individual bubbles are sparsely generated, and a bubble cloud can only be developed with a complex interaction of succeeding cycles, usually by pressure reversal scattering of high peak positive half cycles off individual sparsely distributed seed bubbles generated by previous peak negative half cycles. This process produces a somewhat chaotic multilayer cloud with unpredictable dimensions of each cloud although usually very near the focal volume.


The de novo generated bubble cloud is much more consistent in spatial distribution. Moreover, the diameter of this de novo cloud is determined by the how much of the peak negative part of the waveform exceeds the intrinsic threshold. The amplitude of the waveform can be increased to cause more of the waveform to exceed the threshold, resulting in a larger bubble cloud diameter. The resulting tissue lesion diameter from an increase in the amplitude of the waveform also increases accordingly. Thus in some embodiments, this method, and appropriate hardware, allows a lesion diameter to be modified by changing the intensity of the ultrasound pulse. Moreover, if the pulse consists of only one cycle, with only one peak negative half cycle, pulses below the threshold will not generate bubble clouds because no succeeding positive half-cycles are available for the pressure-release scattering mode to generate a complete bubble cloud. In such circumstances (below de novo threshold), the first peak negative half-cycle would only generate sparsely distributed single bubbles.


Thus, the lower limit in size of a bubble cloud generated lesion is the diameter of a single bubble which is much smaller than the wavelength of the ultrasound waveform producing that bubble, therefore, the approach described herein, which can be referred to herein as “microtripsy”, is capable of generating lesion sizes much smaller than the diffraction limit determined by the frequency of the ultrasound source.


This disclosure provides mechanism for bubble cloud formation different than conventional shock-scattering bubble formation. Apparatus and methods are provided for applying ultrasound pulses into tissue or a medium in which the peak negative pressure (P−) of one or more negative half cycle(s) of the ultrasound pulses exceed(s) an intrinsic threshold of the tissue or medium, to directly form a dense bubble cloud in the tissue or medium without shock-scattering. This intrinsic threshold can be defined by a very sharp transition zone, and can be relatively insensitive to the inhomogeneities in soft tissue or the lack of dissolved gases.


Moreover, this intrinsic threshold may be independent of the applied positive pressure, since the influence of shock-scattering is minimized when applying pulses less than 2 cycles. In some instances, the intrinsic threshold, where there is a high probability of cavitation (formation of a dense bubble cloud) for one single pulse is between 26.4-30.0 MPa in samples with high water content, including water, hydrogel, and soft tissue. In tissue with a higher fat content, including fatty tissues and brain tissue, the intrinsic threshold can be as low as 15 MPa. In one specific embodiment, illustrated by FIG. 2, the intrinsic threshold for a high probability of cavitation in tissue can be approximately 28 MPa. In the chart of FIG. 2, it can be seen that bubbles in this size range display a sharp threshold around a peak negative pressure of ˜28 MPa. Because of the small size of the microbubbles, the cavitation threshold is nearly independent of the frequency range of interest for ultrasound therapy. For example, an intrinsic threshold with a high probability of cavitation has been identified clinically at 28.1 MPa at a frequency of 0.1 MHz, compared to a threshold of 28.4 MPa at 10 MHz.


Because of the sharp, highly repeatable threshold, at negative pressure amplitudes not significantly greater than this, a dense energetic lesion-forming cloud of microbubbles can be generated consistently with a spatial pattern similar to the part of the negative half cycles(s) exceeding the intrinsic threshold. The part of the therapy pulse exceeding intrinsic threshold, and the resulting spatial extent of the lesion forming bubble cloud, are independent of positive shocks and the somewhat chaotic shock-scattering phenomenon. Therefore, the spatial extent of the lesion generated using this mechanism is expected to be well-defined and more predictable. The lesion size can be easily controlled, even for small lesions, simply by a precise adjustment of the therapy pulse amplitude.


Apparatus and methods described herein allow high tissue penetration with minimal aberration and signal degradation while generating acceptably precise lesions. Since clinical targets shadowed by bone are highly attenuating and aberrating, some applicable targets are those reached in the brain (shadowed by skull) or thoracic cavity (shadowed by ribs), although transmission through other complex aberrating tissues is possible, e.g., for trans-uterine procedures.


Lower frequencies propagate much more cleanly through complex media, minimizing aberrations and attenuation, but produce larger lesions, based on the diffraction limit dictating larger focal zones, when conventional ultrasonic therapeutic modalities are used. By using the methods and apparatus described herein, lower frequencies can be used while, at the same time, maintaining small and precise lesion sizes.



FIG. 1 illustrates a Histotripsy system configured to generate cavitation bubbles or bubble clouds in tissue according to the methods and embodiments described herein. A Histotripsy system and generator is configured to generate complex waveforms in order to support the ultrasound pulse sequences described herein. A simplified block diagram of system 100 is shown in FIG. 1. The main components of the system are: Computer/controller 102, USB to Serial Converter 104, Microcontroller 106, FPGA (Field Programmable Gate Array) 108, High Voltage Controller and Power Supply 110, Amplifier 112, and Therapy Transducer 114.


All controls for the generator can be established using a “Histotripsy Service Tool” software that can run on the computer/controller 102 (e.g., a standard PC, laptop, tablet, or other electronic computing system) and communicates to the generator via a connector such as USB serial communication 104. Therapy, including bubble cloud cavitation and tissue ablation can be imaged and tracked in real time using an imaging system 115, such as an ultrasound imaging system or probe.


The system 100 can be configured to receive multiple sets of different driving parameters and loop them, which give the ability to the user to create wide range of custom sequences where all parameters (pulse repetition frequency (PRF), voltage amplitude, number of cycles, number of pulses per set, frequency, transducer element channels enabled, and time delays) can be set differently for every pulse generated. Time delays between pulses can be specified by the PRF for a parameter set or by specifying zero as the number of cycles per pulse.


For overall voltage amplitude regulation, level of high voltage can be changed accordingly through the Microcontroller 106 and HV Controller 110. This method cannot be used for dynamic voltage amplitude changes between two pulses since it will take too long for all capacitors on the HV line to discharge. For dynamic voltage amplitude changes between pulses, PWM (pulse width modulation) can be used at the FPGA 108 where the duty cycle of the pulse may be modulated in order to produce the desired pulse voltage and resultant pressure amplitude.


Histotripsy Service Tool


Histotripsy Service Tool is an application that can be run on any PC or computing system and may be used for controlling the system. The Histotripsy Service Tool can start/stop the therapy, set and read the level of high voltage, therapy parameters (PRF, number of cycles, duty ratio, channel enabled and delay, etc), and set and read other service and maintenance related items.


USB to Serial Converter


USB to Serial converter 104 can convert USB combination to serial in order to communicate to the Microcontroller 106. It should be understood that other converters (or none at all) may be used in embodiments where the connection between the generator and the controller is not a USB connection.


Microcontroller


The Microcontroller 106 communicates to the computer/controller 102 (Histotripsy Service Tool) to set/read working parameters, start/stop the therapy, etc. It can use internal flash memory or other electronic storage media to store all the parameters. The Microcontroller communicates to the FPGA 108 all driving parameters that are necessary to generate complex pulsing. It also communicates using serial communication or other electronic communication to the high voltage controller and power supply 110 where it can set/read the proper level of driving voltage.


FPGA


The FPGA 108 receives the information from the Microcontroller 106 and it can generate the complex pulsing sequence that is required to drive the amplifier 112. The FPGA can run on 100 MHz clock since speed of pulsing is critical to be timed in at least 10 ns increments.


High Voltage Controller and Power Supply


The High Voltage Controller and Power Supply 110 receives the commands from the Microcontroller 106 regarding the level of DC voltage that needs to be supplied to the amplifier circuitry in order to have an adequate voltage amplitude level at the output of the amplifier.


Amplifier


The Amplifier 112 receives pulses generated by the FPGA and is supplied with high voltage from High Voltage Controller and Power Supply. It generates high voltage amplitude pulses that are fed to the Therapy Transducer 114 through the matching network components which properly matches the impedance of the therapy transducer to the impedance of the amplifier. It can be necessary to use a large number of capacitors that can store enough energy to support peak current demand during the generation of high voltage amplitude pulses.


Therapy Transducer


The Therapy Transducer 114 can be a single or multi-element ultrasound therapy transducer configured to generate and deliver the ultrasound therapy pulses described herein into tissue or other mediums. The active transducer elements of the Therapy Transducer can be piezoelectric transducer elements. In some embodiments, the transducer elements can be mounted to an acoustic lens with a common geometric focus.


Imaging System


The system can include an imaging system, such as an ultrasound imaging system, to monitor therapy and track cavitation and tissue ablation in real time. The cavitating bubble cloud generated according to the methods and system of this disclosure can appear as a temporally changing hyperechoic region in B-mode imaging, allowing the treatment to be precisely targeted.


The probability for the generation of a dense bubble cloud using a single, short pulse (≤2 cycles) is a function of the applied peak negative pressure P−. This cavitation probability curve follows a sigmoid function, given by












P
cav



(

p
-

)


=


1
2



[

1
+

erf


(



p
-

-

p





t




2


σ
2




)



]



,




(
1
)







where erf is the error function, pt is the pressure that gives a cavitation probability (Pcav) of 0.5, and σ is a variable that relates to the transition width in the cavitation probability curve, with ±σ giving the difference in pressure for cavitation probability from 0.15 to 0.85. The pt's and σ's in water, gelatin gel, and high water content soft tissue were found to be within the range of 26-30 MPa (pt) and 0.8-1.4 MPa (σ).


An intrinsic pressure threshold is surprisingly similar for cavitation in water, tissue-mimicking phantoms, and tissue. The occurrence of cavitation is a stochastic process; it may or may not occur for a single pulse with finite probability, even though all parameters of the system are identical pulse to pulse. At low pressures, the probability is almost zero and with large enough pressure amplitude the probability is 1 (i.e. cavitation always happens somewhere in the focus). A key factor for microtripsy is that the intrinsic threshold is fairly sharp, meaning there is a small pressure difference between cavitation probabilities of 0 and 1. For instance, in blood or tissue, the probability is near 0 at 25 MPa peak negative pressure and nearly 1 at ˜28 MPa peak negative pressure.


When a pulse passes through an ultrasound transducer focus, different positions in the medium experience different pressures. The center of the focus experiences the greatest pressure amplitude and the focal volume and dimensions are usually determined by the region which experiences peak negative pressures greater than some value relative to the maximum. In our case, we can create a map of the probability of cavitation occurring vs. position for a given pulse. Since there is a small difference in pressure between where cavitation occurs with high probability to where it occurs with very low probability, the boundary is very sharp. If the pressure output is chosen appropriately so that only the center of the focus is just above the threshold, then cavitation is likely to occur only at the focus center, a region which can be considerably smaller than 1 acoustic wavelength. In turn, it is possible that mechanical ablation of tissue smaller than 1 acoustic wavelength can be performed.


To achieve this sort of precision, short-duration (as low as ½ cycle) high peak negative pressure pulses can be generated and focused with the system described above. As described, the peak negative pressure which can be produced at the focus must exceed the intrinsic threshold to produce cavitation. Using long pulses can cause a complex interaction between a few existing microbubbles and the ultrasound pulse. This pulse will scatter from the bubbles and amplify the local pressure, causing a greater number of cavitation bubbles to expand. This limits the possible precision of microtripsy, and is necessarily circumvented by only using short pulses. Transducers to generate this sort of pressure pulse must be highly focused with high bandwidth. This output also requires an electronic driver or amplifier capable of providing the necessary high voltage to the transducer in short pulses.


As described above, an intrinsic threshold in tissue for bubble cavitation can be approximately 28 MPa. For cavitation nuclei in a size range on the order of 2.5 nm, surface tension is the dominant force controlling the threshold by the Laplace pressure. In this respect, it is similar to the Blake threshold. Systems and methods herein can include a frequency range of interest for therapy between 0.1-20 MHz. While the threshold of an individual nucleus may not be a strong function of frequency, the probability of cavitation also depends on the number of nuclei within the focal volume. As such, if an equivalent transducer with a higher frequency were applied, one would expect an incremental increase in the predicted pressure threshold due to the smaller volume of the focus. It appears that a greater negative pressure excursion will activate additional smaller nuclei coexisting with those which cavitate near the 28 MPa threshold.


Systems and methods of producing cavitation in tissue utilizing a “microtripsy” technique will now be described. An ultrasound therapy transducer, such as the transducer and Histotripsy system described in FIG. 1, can be configured to deliver one or more ultrasound pulses into tissue towards a focal point of the transducer. The one or more ultrasound pulses can include at least one negative half cycle. The system is configured to generate cavitation bubble(s) in tissue when the peak negative pressure of the waveform exceeds the intrinsic threshold in the tissue.


In some embodiments, the waveform can be generated such that only a portion of the negative half cycle has a negative pressure exceeding the intrinsic threshold. The portion of the waveform that includes a peak negative pressure greater than the intrinsic threshold in tissue will generate a bubble cloud in the tissue. Thus, the amplitude of the waveform can be adjusted to control the size of the bubble-cloud generated in the tissue. For example, the amplitude of the waveform can be reduced so that only a small portion, or the peak of the waveform exceeds the intrinsic threshold, so as to reduce the size of lesions formed in tissue from the bubble cloud. Alternatively, the amplitude of the waveform can be increased so that all or nearly all of the waveform includes a peak negative pressure that exceeds the intrinsic threshold, thereby creating a larger bubble cloud thereby increasing the size of the lesion in the tissue.


In some embodiments, the ultrasound pulse(s) can have a frequency ranging from 0.1-20 MHz or more. Reducing the frequency, such as applying ultrasound pulses to tissue at 0.1 MHz, facilitates the formation of smaller lesions in tissue with the resulting bubble cloud. Reduced frequencies an also allow bubble cloud formation deeper into tissue due to reduced attenuation.


The ultrasound pulse(s) delivered to tissue can have as few as ½ cycles, as long as at least one of the peak negative pulses exceeds the intrinsic threshold of the tissue. In one embodiment, the Histotripsy system and transducer can be configured to produce and deliver only a monopolar peak negative pulse into the tissue wherein the peak negative pulse exceeds the intrinsic threshold of the tissue.



FIGS. 3A-3B illustrate a beam profile of an ultrasound pulse 316 having a negative half cycle. In the illustrated example, the pulse has a negative pressure ranging from approximately 5 MPa to a peak of approximately 50 MPa. FIG. 3A also shows the intrinsic threshold 318 at which cavitation can be formed in tissue. In this embodiment, the intrinsic threshold is approximately 28 MPa. Referring to FIG. 3A, it can be understood that the portion of the pulse that includes a peak negative pressure exceeding the intrinsic threshold 318 is configured to generate cavitation bubble(s) in the tissue with a high probability. This portion of the pulse that exceeds the intrinsic threshold is illustrated between points 320 and 322.



FIG. 3B shows how the resulting lesion size from cavitation generated by the beam profile can be estimated. In FIG. 3B, a width 324 of the lesion can be estimated by taking the distance between the two points of the beam profile that exceed the intrinsic threshold. Thus in this example, the pulse with a peak negative pressure that exceeds the intrinsic threshold between points 320 and 322 can result in a lesion size estimated to be approximately 2 mm in width.



FIGS. 4A-4B illustrate how adjusting the amplitude of the ultrasound pulse can adjust the amount of cavitation produced, by changing the amount of the waveform that has a peak negative pressure exceeding the intrinsic threshold in tissue. In FIG. 4A, the ultrasound pulse 416 is shown having a negative pressure ranging from approximately 10 MPa to 80 MPa with the intrinsic threshold 418 shown at approximately 28 MPa. In this example, a large portion of the pulse 416 has a negative pressure that exceeds the intrinsic threshold. In FIG. 4B, the amplitude of a subsequent waveform has been decreased to produce a pulse having a negative pressure ranging from approximately 4 MPa to 30 MPa. In this example, only a small portion, or the very tip of the pulse, has a negative pressure that exceeds the intrinsic threshold. Reducing the amplitude of the pulse reduces the amount of the waveform that generates a bubble cloud in tissue, allowing for a smaller and more controlled bubble cloud and thus, a smaller and more controlled lesion in tissue. It should be understood that the amplitudes of subsequent waveforms can also be increased to increase the portion of the waveform that generates a bubble cloud in tissue, allowing for a larger bubble cloud and a larger lesion in tissue.



FIGS. 5A-5C illustrate how adjusting the amplitude or adjusting the portion of the negative half-cycle that exceeds the intrinsic threshold in tissue can affect the amount and size of the bubble cloud and resulting lesion in tissue. As described above, the shape of the bubble cloud generated by the intrinsic threshold mechanism is well-confined and corresponds well to the shape of the transducer focal zone. For illustrative purposes, the bubble clouds 526 shown in FIGS. 5A-5C correspond to a transducer focal zone in the shape of an ellipse or a “football” shape. FIG. 5A can illustrate a baseline bubble cloud 526. In FIG. 5B, the amount and size of the bubble cloud 526 can be increased compared to FIG. 5A by increasing an amplitude of the ultrasound pulse to cause a larger portion of the negative half-cycle to exceed the intrinsic threshold. In contrast, in FIG. 5C, the amount and size of the bubble cloud 526 can be decreased compared to FIG. 5A by decreasing an amplitude of the ultrasound pulse to cause a smaller portion of the negative half-cycle to exceed the intrinsic threshold. The resulting bubble cloud in FIG. 5C shows only a few bubbles generated in tissue.


In some embodiments, microtripsy therapy including the generation of cavitation and ablation of tissues can be monitored under real-time imaging, such as under ultrasound imaging. The real-time imaging can be used to monitor the bubble cloud formation, and also used as feedback to adjust the size of the bubble cloud. For example, in one embodiment, an initial ultrasound pulse having a peak negative pressure that exceeds the intrinsic threshold can be transmitted into tissue to generate a bubble cloud. The size of the bubble cloud can be monitored in real time with the imaging system. Next, a second ultrasound pulse with an amplitude different than the initial ultrasound pulse can be transmitted into the tissue to generate a bubble cloud. If the amplitude of the second ultrasound pulse is less than the initial ultrasound pulse but the pulse still includes a negative pressure above the intrinsic threshold, then the bubble cloud generated will be smaller than was generated with the initial pulse. If the amplitude of the second pulse is larger, then the bubble cloud generated will be greater than with the initial pulse.


Precise and controlled lesions can be generated in tissue using the intrinsic threshold mechanism of Histotripsy therapy described herein. In comparison to the bubble clouds and lesions generated by a shock-scattering mechanism, those generated by the intrinsic threshold mechanism have two advantageous characteristics. First, the shape of the bubble cloud generated by the intrinsic threshold mechanism is well-confined and corresponds well to the shape of the transducer focal zone, whereas the shape of the bubble cloud generated by the shock scattering mechanism is variable and somewhat unpredictable. Because tissue fractionation is directly correlated to the activity of the bubble cloud, the shape of the lesions produced by the intrinsic threshold mechanism is more predictable and has a better agreement to the shape of the transducer focal zone. For waveforms with a peak negative pressure near the intrinsic threshold pressure, single bubbles appear primarily in a region near the center of the focal zone. When the focal pressure is significantly in excess of the cavitation threshold, cavitation bubbles tend to occupy a region similar in shape to the focal zone for each pulse.


Second, the bubble clouds generated by the intrinsic threshold mechanism are more uniform and consistent within the region exceeding the intrinsic threshold, whereas the bubble clouds generated by the shock-scattering mechanism can be isolated to subvolumes of the focus due to complex scattering behavior. Therefore, the intrinsic threshold mechanism can potentially lead to more efficient and complete lesion development in tissue.


Moreover, using this intrinsic threshold mechanism, very small and controlled lesions can be generated by allowing only a small fraction of the focal region to exceed the cavitation threshold. For example, experiments using this method have resulted in lesions with diameters of less than 1 mm. These values were much smaller than the wavelength of the transducer (λ=˜3 mm for 500 kHz) used to generate the lesions. These results demonstrate that microscopic and precise lesions can be achieved using the intrinsic threshold mechanism, which can also be referred to as “microtripsy” herein.


This “microtripsy” technique based on the bubble clouds generated by the intrinsic threshold mechanism can be quite beneficial in the case where microscopic and well-defined tissue ablation is required. Especially, very precise lesions can still be achieved using a low frequency transducer by allowing only a small fraction of the focal zone to exceed the intrinsic threshold. Low frequency transducers would be favorable in applications that require long ultrasound penetration depth or where the intended targets have very attenuative overlying tissues, such as in transcranial brain therapy. Moreover, low-frequency single cycle (or close) pulses minimize phase aberration


This “microtripsy” procedure uses the highly repeatable and very sharp transition zone in cavitation probability inherent to bubble cloud generation above the intrinsic threshold. Lesion sizes in both axial and lateral directions can be increased by increasing the applied peak negative pressure. These lesion sizes corresponded well to the dimensions of the focal beam profile estimated to be beyond the intrinsic cavitation threshold. This “microtripsy” technique can be significantly useful in the clinical applications where precise, microscopic tissue ablation is required, particularly where low frequencies are indicated while still maintaining small precise sub-wavelength lesions.


The aim of a “microtripsy” system can be to generate very short (e.g., as low as one half cycle) high intensity ultrasound pulses wherein the peak negative pressure of the pulse exceeds the intrinsic (or “homogeneous”) threshold in the target media, such as tissue. Therefore, systems, apparatus, and methods described herein are configured to generate bubble clouds of precise and repeatable spatial distribution the diameter, which can be smaller than a wavelength of the ultrasound propagating wave inducing the bubble cloud, i.e., capable of producing lesion diameters “below” the diffraction limit.


The technology described herein allows for applications beyond the physical limitations of current thermal or cavitation based therapeutic modalities. In particular, many advantages derive from employing much lower frequencies while keeping the diameter of generated bubble clouds low (below the diffraction limit). These include: 1. Higher penetration depth, 2. Lower absorption, 3. Lower thermal complications due to heating, 4. Reduced aberration levels, especially through complex tissues including bone, and, 5. Reduced need for aberration correction methods. This can all be accomplished without suffering the usual downside (at lower frequencies) of a larger focal volume and a larger lesion.


The combination of these, and other advantages to be discussed below, will allow targets to be addresses that are currently extremely difficult by noninvasive ultrasonic means. These targets include, but are not limited to: transcranial (through the skull) noninvasive therapeutic procedures including precise lesion formation, immediate (rapid) and noninvasive treatment of stroke inducing blood clots in the brain, brain tumors, and other neural disorders treated by very precise disruption or lesion formation in neural tissues, and precise disruption of the blood brain barrier for drug delivery across drug diffusion-resistant protective membrane systems; trans-thoracic non-invasive procedures through and around the ribs. The largest application can include the treatment of liver mets, direct cardiac ablation for treatment of arrhythmias, treatment of tumors in the spleen, etc. Other applications are considered such as pediatric applications (HLHS, Trans-uterine, etc.) or thrombolysis in small vessels.


All these targets can be reached by using lower frequency ultrasound without giving up precise localization and small lesion size. Moreover, most of the treatments can be delivered by single focus inexpensive transducers without the need for the complex and expensive phased array transducers necessary for aberration correction processes. And, of course, therapy can now be delivered without the expensive means for quantifying the spatial distribution of the acoustic aberrations between the transducer and the target volume (MRI machines, invasive acoustic hydrophones or beacons and associated electronics to determine the quantitative spatial distribution of the acoustic aberrations). The methods disclosed herein are remarkably aberration resistant even not accounting for the possibility, with microtripsy, of using much lower frequencies.


With knowledge of the bubble-cloud dynamics, the pressure thresholds, and the beam pressure profiles for the transducer used for therapy, it can be possible to create a more predictive mechanical ultrasound ablative therapy with cavitation than has been previously achieved. The typical shock-scattering mechanism for forming bubble clouds, which uses multi-cycle pulses, has some limitation, in that it depends on the locations of inhomogeneties and stabilized gas bubbles in the medium to act as single bubble scatterers prior to growing the dense cloud which causes the majority of tissue disruption. Unfortunately, it is very difficult to determine the location of heterogeneous nuclei before treatment, and this can lead to clouds forming in distinct locations in the focal zone while other locations remain completely uncavitated. In contrast, the single pressure excursion pulse described herein can generate cavitation uniformly within the focal zone. While cavitation has generally been regarded as unpredictable in ultrasound therapy, the pulsing regime of this disclosure can create a very controllable situation for planning therapy. Around the cavitation threshold, single bubbles can be generated by a single pulse. In contrast to thermal ultrasound therapy, where applying too great of an acoustic dose can cause damage to collateral tissue by diffusion of heat, the damage with histotripsy can be limited to the focal region and overtreating may have few negative consequences, as the spatial boundary between very high probability and low probability is very narrow because of the intrinsically small value for the probability transition zone σ.


The advantages of bubble cloud generation with as little as a half cycle (or just a few cycles) high intensity pulses with peak negative pressures exceeding the de novo (or homogeneous) threshold are as follows:


The bubble cloud extent can be controlled by the fraction of the peak negative waveform exceeding the intrinsic threshold, which is proportional to pulse intensity. Therefore, the minimum lesion size is limited only by the size of the smallest bubble cloud possible which is the diameter of a single bubble. Bubbles formed near the threshold for a 1 MHz transducer are 100-200 m diameter in tissue, which is 0.06-0.13 wavelengths. Bubbles will grow inversely proportionate to frequency, but their fraction of a wavelength will be similar for most cases. Tissue confinement can limit the maximum expansion of bubbles below these values as well. Therefore, instead of the diffraction limit of several millimeters, the minimum lesion diameter may be as small as 100 micrometers, or a reduction in lesion diameter of an order of magnitude below the diffraction limit.


Smaller bubble clouds mean, for a given fixed lesion diameter, much lower frequencies can be used increasing depth of penetration and decreasing absorption and scattering.


Lower absorption means greatly reduced heating and unwanted hot spots, particularly at tissue boundaries. Such undesired (and unpredictable) thermal consequences often define the limits for certain ultrasound therapies at depth.


Tissue aberrations decrease with frequency allowing much cleaner beams to be formed through complex tissues reducing the need for aberration correction.


The “microtripsy” approach uses the portion of the ultrasound waveform above the intrinsic threshold to generate bubble clouds, thus allowing a large degree of protection against adverse effects of high ultrasound beam side-lobes.


Lower aberrations levels (from the allowed lower frequencies) and the relative insensitivity to aberrations will allow greatly reduced overall system expense by greatly reducing the need for expensive aberration correction hardware and software.


Lower frequencies and lack of need for aberration correction schemes will allow clinical targets like the brain and liver to be treated through the skull and ribs, respectively, without an increase in lesion size.


The de novo generated bubble clouds are remarkably consistent in size for single cycle pulses, and the size can be adjusted by adjusting the pulse amplitude without a need to change the source frequency or the source aperture. As stated several times before, this bubble cloud diameter, and resulting lesion diameter, can be much below the diffraction limit in size.


When bubble clouds are generated by de novo single pulse Histotripsy, the treated volume is remarkably consistent from pulse to pulse with the bubbles forming at random (not predetermined) locations in the focal volume. In other approaches to generating bubble clouds, the location of individual bubbles can depend on memory effects from previous pulses (due to persistent bubble remnants or micronuclei). This memory effect often results in clouds being generated non-homogeneously in the focal volume with some sub-volumes generating no bubbles at all. This results in non-homogeneous lesions in the focal volume with islands of untreated tissues. Many additional pulses are necessary to expand these treated zones to include the un-homogenized islands. Although there are active and passive ways to avoid this memory effect, they require greater complexity.


The zone raised above the de novo threshold (the “de novo volume”) generates bubbles throughout this volume regardless of pre-existing nuclei due to the memory effect, or due to natural dissolved gas, or other cavitation nuclei, in the target volume. Because the de novo threshold is higher than for other forms of cavitation, bubble clouds in the de novo volume tend to be remarkably consistent from pulse to pulse and in different environments.


Because the optimum “microtripsy” pulse comprises at least a single half cycle, the thermal potential of this therapy is minimized due to the very short pulses.


Because the de novo volume is resistant to memory and other pre-existing bubble clouds, much greater pulse repetition frequencies (PRFs) are possible before remnants of previous bubble clouds interfere in a destructive manner in the generation of the latest bubble cloud, a phenomenon common at higher PRFs in other Histotripsy approaches.


Short single cycle pulses are more resistant to aberrations because less time is available for multi-path scattered signals to form up constructively to produce higher side-lobes.


Since the bubble clouds in the de novo volume are not dependent on pressure release scattering from previous bubbles randomly generated by separate multi-cycle bursts or succeeding cycles in a given burst, all below the de novo threshold, the need for more than one initiation pulse (or burst) to get a fully formed bubble cloud disappears.


The data structures and code described in this detailed description are typically stored on a computer-readable storage medium, which may be any device or medium that can store code and/or data for use by a computer system. The computer-readable storage medium includes, but is not limited to, volatile memory, non-volatile memory, magnetic and optical storage devices such as disk drives, magnetic tape, CDs (compact discs), DVDs (digital versatile discs or digital video discs), or other media capable of storing computer-readable media now known or later developed.


The methods and processes described in the detailed description section can be embodied as code and/or data, which can be stored in a computer-readable storage medium as described above. When a computer system reads and executes the code and/or data stored on the computer-readable storage medium, the computer system performs the methods and processes embodied as data structures and code and stored within the computer-readable storage medium.


Furthermore, the methods and processes described above can be included in hardware modules. For example, the hardware modules can include, but are not limited to, application-specific integrated circuit (ASIC) chips, field-programmable gate arrays (FPGAs), and other programmable-logic devices now known or later developed. When the hardware modules are activated, the hardware modules perform the methods and processes included within the hardware modules.


The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.

Claims
  • 1. A method of treating tissue with ultrasound energy, comprising the steps of: delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse comprising only a monopolar peak negative pulse having a peak negative pressure that exceeds an intrinsic threshold in the tissue to produce a bubble cloud of at least one bubble in the tissue; andgenerating a lesion in the tissue with the bubble cloud.
  • 2. The method of claim 1, wherein the ultrasound pulse comprises one half cycle.
  • 3. The method of claim 1 wherein the intrinsic threshold is greater than or equal to 15 MPa peak negative pressure.
  • 4. The method of claim 1 wherein the intrinsic threshold is 28 MPa peak negative pressure.
  • 5. The method of claim 1 wherein the intrinsic threshold is between 26 MPa and 30 MPa peak negative pressure.
  • 6. The method of claim 1 wherein the ultrasound pulse has a frequency between 0.1 MHz and 20 MHz.
  • 7. The method of claim 1 wherein the ultrasound pulse comprises a first ultrasound pulse, the method further comprising delivering a second ultrasound pulse having a smaller amplitude than the first ultrasound pulse, such that a peak negative pressure of the second ultrasound pulse exceeds the intrinsic threshold but is smaller than the peak negative pressure of the first ultrasound pulse.
  • 8. The method of claim 7, wherein the second ultrasound pulse produces a smaller bubble cloud than the first ultrasound pulse.
  • 9. The method of claim 1 wherein the ultrasound pulse comprises a first ultrasound pulse, the method further comprising delivering a second ultrasound pulse having a larger amplitude than the first ultrasound pulse, such that a peak negative pressure of the second ultrasound pulse exceeds the intrinsic threshold but is larger than the peak negative pressure of the first ultrasound pulse.
  • 10. The method of claim 9, wherein the second ultrasound pulse produces a larger bubble cloud than the first ultrasound pulse.
  • 11. The method of claim 1, wherein the bubble cloud is formed in the tissue without shock-scattering.
  • 12. A method of treating tissue with ultrasound energy, comprising the steps of: delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse comprising only a monopolar peak negative pulse having a peak negative pressure that exceeds 28 MPa in the tissue to produce a bubble cloud in the tissue; andgenerating a lesion in the tissue with the bubble cloud.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. 119 of U.S. Provisional Patent Application No. 61/868,992, filed Aug. 22, 2013, titled “Histotripsy Using Very Short Ultrasound Pulses”, which application is incorporated herein by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with Government support under Grants CA134579 and EB008998 awarded by the National Institutes of Health. The Government has certain rights in the invention.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2014/052310 8/22/2014 WO 00
Publishing Document Publishing Date Country Kind
WO2015/027164 2/26/2015 WO A
US Referenced Citations (379)
Number Name Date Kind
3243497 Kendall et al. Mar 1966 A
3679021 Goldberg et al. Jul 1972 A
3879699 Pepper Apr 1975 A
4016749 Wachter Apr 1977 A
4024501 Herring et al. May 1977 A
4051394 Tieden Sep 1977 A
4117446 Alais Sep 1978 A
4266747 Souder, Jr. et al. May 1981 A
4269174 Adair May 1981 A
4277367 Madsen et al. Jul 1981 A
4351038 Alais Sep 1982 A
4406153 Ophir et al. Sep 1983 A
4440025 Hayakawa et al. Apr 1984 A
4447031 Souder, Jr. et al. May 1984 A
4453408 Clayman Jun 1984 A
4483345 Miwa Nov 1984 A
4548374 Thompson et al. Oct 1985 A
4549533 Cain et al. Oct 1985 A
4550606 Drost Nov 1985 A
4551794 Sandell Nov 1985 A
4575330 Hull Mar 1986 A
4622972 Giebeler, Jr. Nov 1986 A
4625731 Quedens et al. Dec 1986 A
4641378 McConnell et al. Feb 1987 A
4669483 Hepp et al. Jun 1987 A
4689986 Carson et al. Sep 1987 A
4757820 Itoh Jul 1988 A
4791915 Barsotti et al. Dec 1988 A
4819621 Ueberle et al. Apr 1989 A
4829491 Saugeon et al. May 1989 A
4856107 Dory Aug 1989 A
4865042 Umemura et al. Sep 1989 A
4888746 Wurster et al. Dec 1989 A
4890267 Rudolph Dec 1989 A
4922917 Dory May 1990 A
4938217 Lele Jul 1990 A
4957099 Hassler Sep 1990 A
4973980 Howkins et al. Nov 1990 A
4984575 Uchiyama et al. Jan 1991 A
4991151 Dory Feb 1991 A
4995012 Dory Feb 1991 A
RE33590 Dory May 1991 E
5014686 Schafer May 1991 A
5065751 Wolf Nov 1991 A
5080101 Dory Jan 1992 A
5080102 Dory Jan 1992 A
5091893 Smith et al. Feb 1992 A
5092336 Fink Mar 1992 A
5097709 Masuzawa et al. Mar 1992 A
5111822 Dory May 1992 A
5143073 Dory Sep 1992 A
5143074 Dory Sep 1992 A
5150711 Dory Sep 1992 A
5158070 Dory Oct 1992 A
5158071 Umemura et al. Oct 1992 A
5163421 Bernstein et al. Nov 1992 A
5165412 Okazaki Nov 1992 A
5174294 Saito et al. Dec 1992 A
5209221 Riedlinger May 1993 A
5215680 D'Arrigo Jun 1993 A
5219401 Cathignol et al. Jun 1993 A
5222806 Roberts Jun 1993 A
5230340 Rhyne Jul 1993 A
5295484 Marcus et al. Mar 1994 A
5316000 Chapelon et al. May 1994 A
5354258 Dory Oct 1994 A
5380411 Schlief Jan 1995 A
5393296 Rattner Feb 1995 A
5409002 Pell Apr 1995 A
5431621 Dory Jul 1995 A
5435311 Umemura et al. Jul 1995 A
5443069 Schaetzle Aug 1995 A
5450305 Boys et al. Sep 1995 A
5469852 Nakamura et al. Nov 1995 A
5474071 Chapelon et al. Dec 1995 A
5474531 Carter Dec 1995 A
5490051 Messana Feb 1996 A
5501655 Rolt et al. Mar 1996 A
5520188 Hennige et al. May 1996 A
5523058 Umemura et al. Jun 1996 A
5524620 Rosenschein Jun 1996 A
5540909 Schutt Jul 1996 A
5542935 Unger et al. Aug 1996 A
5558092 Unger et al. Sep 1996 A
5563346 Bartelt et al. Oct 1996 A
5566675 Li et al. Oct 1996 A
5573497 Chapelon Nov 1996 A
5580575 Unger et al. Dec 1996 A
5582578 Zhong et al. Dec 1996 A
5590657 Cain et al. Jan 1997 A
5601526 Chapelon et al. Feb 1997 A
5617862 Cole et al. Apr 1997 A
5648098 Porter Jul 1997 A
5666954 Chapelon et al. Sep 1997 A
5676452 Scholz Oct 1997 A
5676692 Sanghvi et al. Oct 1997 A
5678554 Hossack et al. Oct 1997 A
5694936 Fujimoto Dec 1997 A
5695460 Siegel et al. Dec 1997 A
5717657 Ruffa Feb 1998 A
5724972 Petrofsky Mar 1998 A
5743863 Chapelon Apr 1998 A
5753929 Bliss May 1998 A
5759162 Oppelt et al. Jun 1998 A
5766138 Rattner Jun 1998 A
5769790 Watkins et al. Jun 1998 A
5797848 Marian et al. Aug 1998 A
5823962 Schaetzle et al. Oct 1998 A
5827204 Grandia et al. Oct 1998 A
5836896 Rosenschein Nov 1998 A
5849727 Porter et al. Dec 1998 A
5873902 Sanghvi et al. Feb 1999 A
5879314 Peterson et al. Mar 1999 A
5932807 Mallart Aug 1999 A
5947904 Hossack et al. Sep 1999 A
6001069 Tachibana et al. Dec 1999 A
6022309 Celliers et al. Feb 2000 A
6036667 Manna et al. Mar 2000 A
6088613 Unger Jul 2000 A
6093883 Sanghvi et al. Jul 2000 A
6113558 Rosenschein et al. Sep 2000 A
6126607 Whitmore, III et al. Oct 2000 A
6128958 Cain Oct 2000 A
6143018 Beuthan et al. Nov 2000 A
6165144 Talish et al. Dec 2000 A
6176842 Tachibana et al. Jan 2001 B1
6296619 Brisken Oct 2001 B1
6308585 Nilsson et al. Oct 2001 B1
6308710 Silva Oct 2001 B1
6309355 Cain et al. Oct 2001 B1
6318146 Madsen et al. Nov 2001 B1
6321109 Ben-Haim et al. Nov 2001 B2
6338566 Verdier Jan 2002 B1
6344489 Spears Feb 2002 B1
6391020 Kurtz et al. May 2002 B1
6413216 Cain et al. Jul 2002 B1
6419648 Vitek et al. Jul 2002 B1
6470204 Uzgiris et al. Oct 2002 B1
6488639 Ribault et al. Dec 2002 B1
6490469 Candy Dec 2002 B2
6500141 Mon et al. Dec 2002 B1
6506154 Ezion et al. Jan 2003 B1
6506171 Vitek et al. Jan 2003 B1
6508774 Acker et al. Jan 2003 B1
6511428 Azuma et al. Jan 2003 B1
6511444 Hynynen et al. Jan 2003 B2
6522142 Freundlich Feb 2003 B1
6524251 Rabiner et al. Feb 2003 B2
6536553 Scanlon Mar 2003 B1
6543272 Vitek Apr 2003 B1
6556750 Constantino et al. Apr 2003 B2
6559644 Froundlich et al. May 2003 B2
6576220 Unger Jun 2003 B2
6599288 Maguire et al. Jul 2003 B2
6607498 Eshel Aug 2003 B2
6612988 Maor et al. Sep 2003 B2
6613004 Vitek et al. Sep 2003 B1
6613005 Friedman et al. Sep 2003 B1
6626854 Friedman et al. Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6645162 Friedman et al. Nov 2003 B2
6648839 Manna et al. Nov 2003 B2
6666833 Friedman et al. Dec 2003 B1
6685640 Fry et al. Feb 2004 B1
6685657 Jones Feb 2004 B2
6705994 Vortman et al. Mar 2004 B2
6719449 Laugharn, Jr. et al. Apr 2004 B1
6719694 Weng et al. Apr 2004 B2
6735461 Vitek et al. May 2004 B2
6736814 Manna et al. May 2004 B2
6750463 Riley Jun 2004 B1
6770031 Hynynen et al. Aug 2004 B2
6775438 Gaedke et al. Aug 2004 B1
6788977 Fenn et al. Sep 2004 B2
6790180 Vitek Sep 2004 B2
6820160 Allman Nov 2004 B1
6852082 Strickberger et al. Feb 2005 B2
6869439 White et al. Mar 2005 B2
6890332 Truckai et al. May 2005 B2
6929609 Asafusa Aug 2005 B2
7004282 Manna et al. Feb 2006 B2
7059168 Hibi et al. Jun 2006 B2
7128711 Medan et al. Oct 2006 B2
7128719 Rosenberg Oct 2006 B2
7175596 Vitek et al. Feb 2007 B2
7196313 Quinones Mar 2007 B2
7223239 Schulze et al. May 2007 B2
7258674 Cribbs et al. Aug 2007 B2
7273458 Prausnitz et al. Sep 2007 B2
7273459 Desilets et al. Sep 2007 B2
7300414 Holland et al. Nov 2007 B1
7311679 Desilets et al. Dec 2007 B2
7331951 Eshel et al. Feb 2008 B2
7341569 Soltani et al. Mar 2008 B2
7347855 Eshel et al. Mar 2008 B2
7358226 Dayton et al. Apr 2008 B2
7359640 Onde et al. Apr 2008 B2
7367948 O'Donnell et al. May 2008 B2
7374551 Liang et al. May 2008 B2
7377900 Vitek et al. May 2008 B2
7429249 Winder et al. Sep 2008 B1
7431704 Babaev Oct 2008 B2
7442168 Novak et al. Oct 2008 B2
7462488 Madsen et al. Dec 2008 B2
7559905 Kagosaki et al. Jul 2009 B2
7656638 Laakso et al. Feb 2010 B2
7695437 Quistgaard et al. Apr 2010 B2
7714481 Sakai May 2010 B2
7771359 Adam Aug 2010 B2
7967763 Deem et al. Jun 2011 B2
8057408 Cain et al. Nov 2011 B2
8295912 Gertner Oct 2012 B2
8333115 Garvey et al. Dec 2012 B1
8337407 Quistgaard et al. Dec 2012 B2
8342467 Stachowski et al. Jan 2013 B2
8376970 Babaev Feb 2013 B2
8539813 Cain et al. Sep 2013 B2
8568339 Rybyanets Oct 2013 B2
8636664 Brannan Jan 2014 B2
8715187 Landberg Davis et al. May 2014 B2
8845537 Tanaka et al. Sep 2014 B2
8932239 Sokka et al. Jan 2015 B2
9028434 Tanaka May 2015 B2
9049783 Teofilovic Jun 2015 B2
9061131 Jahnke et al. Jun 2015 B2
9144694 Cain Sep 2015 B2
9220476 Coussios et al. Dec 2015 B2
9228730 Inbody Jan 2016 B1
9302124 Konofagou et al. Apr 2016 B2
9457201 Hoelscher et al. Oct 2016 B2
9763688 Stulen et al. Sep 2017 B2
10046181 Barthe et al. Aug 2018 B2
10058352 Carvell et al. Aug 2018 B2
10130828 Vortman et al. Nov 2018 B2
20010039420 Burbank et al. Nov 2001 A1
20010041163 Sugita Nov 2001 A1
20020045890 Celliers et al. Apr 2002 A1
20020078964 Kovac et al. Jun 2002 A1
20020099356 Unger et al. Jul 2002 A1
20020145091 Talish et al. Oct 2002 A1
20030092982 Eppstein May 2003 A1
20030112922 Burdette et al. Jun 2003 A1
20030149352 Liang et al. Aug 2003 A1
20030157025 Unger et al. Aug 2003 A1
20030169591 Cochran Sep 2003 A1
20030181833 Faragalla et al. Sep 2003 A1
20030199857 Eizenhofer Oct 2003 A1
20030221561 Milo Dec 2003 A1
20030236539 Rabiner et al. Dec 2003 A1
20040127815 Marchitto et al. Jul 2004 A1
20040138563 Moehring et al. Jul 2004 A1
20040236248 Svedman Nov 2004 A1
20040243021 Murphy et al. Dec 2004 A1
20040260214 Echt Dec 2004 A1
20050020945 Tosaya et al. Jan 2005 A1
20050038339 Chauhan et al. Feb 2005 A1
20050038361 Thong et al. Feb 2005 A1
20050152561 Spencer Jul 2005 A1
20050154314 Quistgaard Jul 2005 A1
20050234438 Mast et al. Oct 2005 A1
20050283098 Conston et al. Dec 2005 A1
20060060991 Holsteyns et al. Mar 2006 A1
20060074303 Chornenky et al. Apr 2006 A1
20060173387 Hansmann et al. Aug 2006 A1
20060206028 Lee et al. Sep 2006 A1
20060241466 Ottoboni et al. Oct 2006 A1
20060241523 Sinelnikov et al. Oct 2006 A1
20060241533 Geller Oct 2006 A1
20060264760 Liu et al. Nov 2006 A1
20060293630 Manna et al. Dec 2006 A1
20070010805 Fedewa et al. Jan 2007 A1
20070016039 Vortman et al. Jan 2007 A1
20070044562 Sarr Mar 2007 A1
20070065420 Johnson Mar 2007 A1
20070083120 Cain et al. Apr 2007 A1
20070161902 Dan Jul 2007 A1
20070167764 Hynynen Jul 2007 A1
20070205785 Nilsson Sep 2007 A1
20070219448 Seip et al. Sep 2007 A1
20080013593 Kawabata Jan 2008 A1
20080055003 Unnikrishnan et al. Mar 2008 A1
20080082026 Schmidt et al. Apr 2008 A1
20080091125 Owen et al. Apr 2008 A1
20080126665 Burr et al. May 2008 A1
20080177180 Azhari et al. Jul 2008 A1
20080194965 Sliwa et al. Aug 2008 A1
20080214964 Chapelon et al. Sep 2008 A1
20080262345 Fichtinger et al. Oct 2008 A1
20080262486 Zvuloni et al. Oct 2008 A1
20080312561 Chauhan Dec 2008 A1
20080319356 Cain Dec 2008 A1
20080319376 Wilcox et al. Dec 2008 A1
20090030339 Cheng et al. Jan 2009 A1
20090112098 Vaezy et al. Apr 2009 A1
20090177085 Maxwell et al. Jul 2009 A1
20090198094 Fenster et al. Aug 2009 A1
20090211587 Lawrentschuk Aug 2009 A1
20090227874 Suri et al. Sep 2009 A1
20090230822 Kushculey et al. Sep 2009 A1
20090287083 Kushculey et al. Nov 2009 A1
20100011845 Laugharn et al. Jan 2010 A1
20100056924 Powers Mar 2010 A1
20100059264 Hasegawa et al. Mar 2010 A1
20100069797 Cain et al. Mar 2010 A1
20100125225 Gelbart et al. May 2010 A1
20100152624 Tanis et al. Jun 2010 A1
20100163694 Fadler et al. Jul 2010 A1
20100261994 Davalos et al. Oct 2010 A1
20100274136 Cerofolini Oct 2010 A1
20100286519 Lee et al. Nov 2010 A1
20100298744 Altshuler et al. Nov 2010 A1
20100305432 Duhay et al. Dec 2010 A1
20100317971 Fan et al. Dec 2010 A1
20100318002 Prus et al. Dec 2010 A1
20110054315 Roberts et al. Mar 2011 A1
20110054363 Cain et al. Mar 2011 A1
20110112400 Emery et al. May 2011 A1
20110118602 Weng et al. May 2011 A1
20110144490 Davis et al. Jun 2011 A1
20110144545 Fan et al. Jun 2011 A1
20110172529 Gertner Jul 2011 A1
20110178444 Slayton et al. Jul 2011 A1
20110245671 Sato Oct 2011 A1
20110251528 Canney et al. Oct 2011 A1
20110257524 Gertner Oct 2011 A1
20110263967 Bailey et al. Oct 2011 A1
20120010541 Cain et al. Jan 2012 A1
20120029353 Slayton et al. Feb 2012 A1
20120029393 Lee Feb 2012 A1
20120059264 Hope Simpson et al. Mar 2012 A1
20120059285 Soltani et al. Mar 2012 A1
20120092724 Pettis Apr 2012 A1
20120130288 Holland et al. May 2012 A1
20120136279 Tanaka et al. May 2012 A1
20120158013 Stefanchik et al. Jun 2012 A1
20120172720 Kawabata Jul 2012 A1
20120189998 Kruecker et al. Jul 2012 A1
20120232388 Curra et al. Sep 2012 A1
20120259250 Sapozhnikov et al. Oct 2012 A1
20120271167 Holland et al. Oct 2012 A1
20120271223 Khanna Oct 2012 A1
20130051178 Rybyanets Feb 2013 A1
20130053691 Kawabata et al. Feb 2013 A1
20130090579 Cain et al. Apr 2013 A1
20130102932 Cain et al. Apr 2013 A1
20130144165 Ebbini Jun 2013 A1
20130190623 Bertolina et al. Jul 2013 A1
20130255426 Kassow et al. Oct 2013 A1
20130289593 Hall et al. Oct 2013 A1
20130303906 Cain et al. Nov 2013 A1
20140058293 Hynynen et al. Feb 2014 A1
20140073995 Teofilovic et al. Mar 2014 A1
20140100459 Xu et al. Apr 2014 A1
20140128734 Genstler et al. May 2014 A1
20140200489 Behar et al. Jul 2014 A1
20140330124 Carol Nov 2014 A1
20150011916 Cannata et al. Jan 2015 A1
20150151141 Arnal et al. Jun 2015 A1
20150190121 Slayton et al. Jul 2015 A1
20150258352 Lin et al. Sep 2015 A1
20150273246 Darlington et al. Oct 2015 A1
20150290477 Jahnke et al. Oct 2015 A1
20150297177 Boctor et al. Oct 2015 A1
20150375015 Cain Dec 2015 A1
20160151618 Powers et al. Jun 2016 A1
20160184614 Matula et al. Jun 2016 A1
20160206867 Hossack et al. Jul 2016 A1
20160287909 Maxwell et al. Oct 2016 A1
20160339273 Al Mayiah Nov 2016 A1
20170000376 Partanen et al. Jan 2017 A1
20170049463 Popovic et al. Feb 2017 A1
20170071515 Chevillet et al. Mar 2017 A1
20170072227 Khokhlova et al. Mar 2017 A1
20170072228 Wang et al. Mar 2017 A1
20170120080 Phillips et al. May 2017 A1
20170165046 Johnson et al. Jun 2017 A1
20180154186 Xu et al. Jun 2018 A1
20190216478 Maxwell et al. Jul 2019 A1
20190275353 Cannata et al. Sep 2019 A1
Foreign Referenced Citations (53)
Number Date Country
1669672 Sep 2005 CN
1732031 Feb 2006 CN
201197744 Feb 2009 CN
102292123 Dec 2011 CN
102481164 May 2012 CN
102665585 Sep 2012 CN
103537016 Jan 2014 CN
103648361 Mar 2014 CN
103812477 May 2014 CN
104013444 Sep 2014 CN
104135938 Nov 2014 CN
3220751 Dec 1983 DE
3544628 Jun 1987 DE
3817094 Nov 1989 DE
4012760 May 1992 DE
0017382 Oct 1980 EP
0320303 Jun 1989 EP
0332871 Sep 1989 EP
0384831 Aug 1990 EP
0755653 Jan 1997 EP
1374785 Jan 2004 EP
1504713 Feb 2005 EP
2397188 Dec 2011 EP
2099582 Dec 1982 GB
60-80779 May 1985 JP
61-196718 Aug 1986 JP
02-215451 Aug 1990 JP
06-197907 Jul 1994 JP
07-504339 May 1995 JP
08-84740 Apr 1996 JP
06-304178 May 1996 JP
08-131454 May 1996 JP
09-55571 Feb 1997 JP
HEI10-512477 Dec 1998 JP
2000300559 Oct 2000 JP
2003-510159 Mar 2003 JP
2004-505660 Feb 2004 JP
2005167058 Jun 2005 JP
2007144225 Jun 2007 JP
2007520307 Jul 2007 JP
2010019554 Jan 2010 JP
2010029650 Feb 2010 JP
2010204068 Sep 2010 JP
2004-512502 Apr 2014 JP
WO 9406355 Mar 1994 WO
WO 0232506 Apr 2002 WO
WO2005018469 Mar 2005 WO
WO 2008051484 May 2008 WO
WO2011040054 Jul 2011 WO
WO 2011092683 Aug 2011 WO
WO2011154654 Dec 2011 WO
WO2014071386 May 2014 WO
WO2015000953 Jan 2015 WO
Non-Patent Literature Citations (99)
Entry
Sferruzza et al. “Generation of high power unipolar pulse with a piezocomposite transducer,” 1999 IEEE Ultrasonics Symposium. Proceedings. International Symposium (Cat. No. 99CH37027), Caesars Tahoe, NV, 1999, pp. 1125-1128 vol. 2. (Year: 1999).
Bak; Rapid protytyping or rapid production? 3D printing processes move industry towards the latter; Assembly Automation; 23(4); pp. 340-345; Dec. 1, 2003.
Shung; Diagnostic Ultrasound: Imaging and Blood Flow Measurements; Taylor and Francis Group, LLC; Boca Raton, FL; 207 pages; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 2006.
Wikipedia; Medical ultrasound; 15 pages; retrieved from the internet (https://en.wikipedia.org/w/index.php?title=Medical_utrasound&oldid=515340960) on Jan. 12, 2018.
Xu et al.; U.S. Appl. No. 15/713,441 entitled “Bubble-induced color doppler feedback during histotripsy,” filed Sep. 22, 2017.
Hobarth et al.; Color flow doppler sonography for extracorporal shock wave lithotripsy; Journal of Urology; 150(6); pp. 1768-1770; Dec. 1, 1993.
Maxwell et al.; In-vivo study of non-invasive thrombolysis by histotripsy in a porcine model; IEEE international Ultrasonics Symposium; IEEE; p. 220-223; Sep. 20, 2009.
Urban et al.; Measurement of prostate viscoelasticity using shearwave dispersion ultrasound vibrometry (SDUV): an in vitro study; IEEE International Ultrasonics Symposium Proceedings (IUS); pp. 1141-1144; Oct. 11, 2010.
Akiyama et al.; Elliptically curved acoustic lens for emitting strongly focused finite-amplitude beams: Application of the spheroidal beam equation model to the theoretical prediction; Acoustical Science and Technology, vol. 26, pp. 279-284, May 2005.
Appel et al.; Stereoscopic highspeed recording of bubble filaments; Ultrasonics Sonochemistry; vol. 11(1); pp. 39-42; Jan. 2004.
Aram et al.; Transurethral prostate magnetic resonance elestography; prospective imaging requirements; Magn. Reson. Med.; 65(2); pp. 340-349; Feb. 2011.
Aschoff et al.; How does alteration of hepatic blood flow affect liver perfusion and radiofrequency-induced thermal lesion size in rabbit liver?; J Magn Reson Imaging; 13(1); pp. 57-63; Jan. 2001.
Atchley et al.; Thresholds for cavitation produced in water by pulsed ultrasound; Ultrasonics.; vol. 26(5); pp. 280-285; Sep. 1988.
Avago Technologies; ACNV2601 High Insulation Voltage 10 MBd Digital Opotcoupler. Avago Technologies Data Sheet; pp. 1-11; Jul. 29, 2010.
Avago Technologies; Avago's ACNV2601 optocoupler is an optically coupled logic gate; Data Sheet; 2 pages; Jul. 29, 2010.
Avtech; AVR-8 Data sheet; May 23, 2004; 3 pages; retrieved from the internet (http//www.avtechpulse.com).
Billson et al.; Rapid prototyping technologies for ultrasonic beam focussing in NDE; IEEE International Ultrasonic Symposium Proceedings; pp. 2472-2472; Oct. 2011.
Bjoerk et al.; Cool/MOS CP—How to make most beneficial use of the generation of super junction technology devices. Infineon Technologies AG. [retrieved Feb. 4, 2014] from the internet (http://www.infineon.com/dgdl/Infineon+-=Application+Note+-+PowerMOSFETs+-+600V+CoolMOS%E284%A2+-+CP+Most+beneficial+use+of+superjunction+technologie+devices.pdf?folderId=db3a304412b407950112b408e8c90004&fileId=db3a304412b407950112b40ac9a40688>pp. 1, 4, 14; Feb. 2007.
Bland et al.; Surgical Oncology; McGraw Hill; Chap. 5 (Cavitron Ultrasonic Aspirator); pp. 461-462; Jan. 29, 2001.
Burdin et al.; Implementation of the laser diffraction technique for cavitation bubble investigations; Particle & Particle Systems Characterization; vol. 19; pp. 73-83; May 2002.
Cain, Charles A.; Histotripsy: controlled mechanical sub-division of soft tissues by high intensity pulsed ultrasound (conference presentation); American Institute of Physics (AIP) Therapeutic Ultrasound: 5th International Symposium on Therapeutic Ultrasound; 44 pgs.; Oct. 27-29, 2005.
Canney et al.; Shock-Induced Heating and Millisecond Boiling in Gels and Tissue Due to High Intensity Focused Ultrasound; Ultrasound in Medicine & Biology, vol. 36, pp. 250-267; Feb. 2010 (author manuscript).
Chan et al.; An image-guided high intensity focused ultrasound device for uterine fibroids treatment; Medical Physics, vol. 29, pp. 2611-2620, Nov. 2002.
Clasen et al.; MR-guided radiofrequency ablation of hepatocellular carcinoma: Long-term effectiveness; J Vase Intery Radiol; 22(6); pp. 762-770; Jun. 2011.
Clement et al.; A hemisphere array for non-invasive ultrasound brain therapy and surgery; Physics in Medicine and Biology, vol. 45, p. 3707-3719, Dec. 2000.
Cline et al.; Magnetic resonance-guided thermal surgery; Magnetic Resonance in Medicine; 30(1); pp. 98-106; Jul. 1993.
Curiel et al.; Elastography for the follow-up of high-intensity focused ultrasound prostate cancer treatment: Initial comparison with MRI; Ultrasound Med. Biol; 31(11); pp. 1461-1468; Nov. 2005.
Desilets et al.; The Design of Efficient Broad-Band Piezoelectric Transducers; Sonics and Ultrasonics, IEEE Transactions on, vol. 25, pp. 115-125, May 1978.
Emelianov et al.; Triplex ultrasound: Elasticity imaging to age deep venous thrombosis; Ultrasound Med Biol; 28(6); pp. 757-767; Jun. 2002.
Giannatsis et al.; Additive fabrication technologies applied to medicine and health care: a review; The International Journal of Advanced Manufacturing Technology; 40(1-2); pp. 116-127; Jan. 2009.
Gudra et al.; Influence of acoustic impedance of multilayer acoustic systems on the transfer function of ultrasonic airborne transducers; Ultrasonics, vol. 40, pp. 457-463, May 2002.
Hall et al.; A Low Cost Compact 512 Channel Therapeutic Ultrasound System for Transcutaneous Ultrasound Surgery; AIP Conference Proceedings, Boston, MA; vol. 829, pp. 445-449, Oct. 27-29, 2005.
Hall et al.; Acoustic Access to the Prostate for Extracorporeal Ultrasound Ablation; Journal of Endourology, vol. 24, pp. 1875-1881, Nov. 2010.
Hall et al.; Histotripsy of the prostate: dose effects in a chronic canine model; Urology; 74(4); pp. 932-937; Oct. 2009 (author manuscript).
Hall et al.; Imaging feedback of tissue liquefaction (histotripsy) in ultrasound surgery; IEEE Ultrasonic Symposium, Sep. 18-21, 2005, pp. 1732-1734.
Hartmann; Ultrasonic properties of poly(4-methyl pentene-1), Journal of Applied Physics, vol. 51, pp. 310-314, Jan. 1980.
Holland et al.; Thresholds for transient cavitation produced by pulsed ultrasound in a controlled nuclei environment; J. Acoust. Soc. Am.; vol. 88(5); pp. 2059-2069; Nov. 1990.
Huber et al.; Influence of shock wave pressure amplitude and pulse repetition frequency on the lifespan, size and number of transient cavities in the field of an electromagnetic lithotripter; Physics in Medicine and Biology; vol. 43(10); pp. 3113-3128; Oct. 1998.
Hynynen et al.; Tissue thermometry during ultrasound exposure; European Urology; 23(Suppl 1); pp. 12-16; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date)1993.
Kallel et al.; The feasibility of elastographic visualization of HIFU-induced thermal lesions in soft tissues: Image-guided high-intensity focused ultrasound; Ultrasound Med. Biol; 25(4); pp. 641-647; May 1999.
Khokhlova et al.; Controlled tissue emulsification produced by high intensity focused ultrasound shock waves and millisecond boiling; J. Acoust. Soc. Am.; 130(5), pt. 2; pp. 3498-3510; Nov. 2011.
Kim et al.; Dependence of particle volume fraction on sound velocity and attenuation of EPDM composites; Ultrasonics, vol. 46, pp. 177-183, Feb. 2007.
Konofagou; Quo vadis elasticity imaging?; Ultrasonics; 42(1-9); pp. 331-336; Apr. 2004.
Krimholtz et al.; New equivalent circuits for elementary piezoelectric transducers; Electronics Letters, vol. 6, pp. 398-399, Jun. 1970.
Kruse et al.; Tissue characterization using magnetic resonance elastography: Preliminary results; Phys. Med. Biol; 45(6); pp. 1579-1590; Jun. 2000.
Lake et al.; Histotripsy: minimally invasive technology for prostatic tissue ablation in an in vivo canine model; Urology; 72(3); pp. 682-686; Sep. 2008.
Lauterborn et al.; Cavitation bubble dynamics studied by high speed photography and holography: part one; Ultrasonics; vol. 23; pp. 260-268; Nov. 1985.
Lensing et al.; Deep-vein thrombosis; The Lancet, vol. 353, pp. 479-485, Feb. 6, 1999.
Lin et al; Dual-beam histotripsy: a low-frequency pump enabling a high-frequency probe for precise lesion formation; IEEE Trans. Ultrason. Ferroelectr. Control; 61(2); pp. 325-340; Feb. 2014; (Author Manuscript; 29 pages).
Liu et al.; Real-time 2-D temperature imaging using ultrasound; IEEE Trans Biomed Eng; 57(1); pp. 12-16; Jan. 2010 (author manuscript, 16 pgs.).
Liu et al.; Viscoelastic property measurement in thin tissue constructs using ultrasound; IEEE Trans Ultrason Ferroelectr Freq Control; 55(2); pp. 368-383; Feb. 2008 (author manuscript, 37 pgs.).
Manes et al.; Design of a Simplified Delay System for Ultrasound Phased Array Imaging; Sonics and Ultrasonics, IEEE Transactions on, vol. 30, pp. 350-354, Nov. 1983.
Maréchal et al; Effect of Radial Displacement of Lens on Response of Focused Ultrasonic Transducer; Japanese Journal of Applied Physics, vol. 46, p. 3077-3085; May 15, 2007.
Maréchal et al; Lens-focused transducer modeling using an extended KLM model; Ultrasonics, vol. 46, pp. 155-167, May 2007.
Martin et al.; Water-cooled, high-intensity ultrasound surgical applicators with frequency tracking; Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on, vol. 50, pp. 1305-1317, Oct. 2003.
Maxwell et al.; Cavitation clouds created by shock scattering from bubbles during histotripsy; J. Acoust. Soc. Am.; 130(4); pp. 1888-1898; Oct. 2011.
Maxwell et al.; Noninvasive Thrombolysis Using Pulsed Ultrasound Cavitation Therapy—Histotripsy; Ultrasound in Medicine & Biology, vol. 35, pp. 1982-1994, Dec. 2009 (author manuscript).
Maxwell; Noninvasive thrombolysis using histotripsy pulsed ultrasound cavitation therapy; PhD Dissertation. University of Michigan, Ann Arbor, Michigan. Jun. 2012.
Miller et al.; A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective; Ultrasound in Medicine and Biology; vol. 22; pp. 1131-1154; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1996.
Miller et al.; Investigation of the mechanism of ARFI-based color doppler feedback of histotripsy tissue fractionation; Ultrasonic Symposium (IUS); 2013 IEEE International; 4 pages; Jul. 21-25, 2013.
Miller et al.; Real-time elastography-based monitoring of histotripsy tissue fractionation using color doppler; Ultrasonics Symposium (IUS); 2012 IEEE International; 8 pages; Oct. 7-10, 2012.
Nightingale et al.; Analysis of contrast in images generated with transient acoustic radiation force; Ultrasound Med Biol; 32(1); pp. 61-72; Jan. 2006.
Ohl et al.; Bubble dynamics, shock waves and sonoluminescence; Phil. Trans. R. Soc. Lond. A; vol. 357; pp. 269-294; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1999.
Okada et al.; A case of hepatocellular carcinoma treated by MR-guided focused ultrasound ablation with respiratory gating; Magn Reson Med Sci; 5(3); pp. 167-171; Oct. 2006.
Palmeri et al.; Acoustic radiation force-based elasticity imaging methods; Interface Focus; 1; pp. 553-564; Aug. 2011.
Parsons et al.; Cost-effective assembly of a basic fiber-optic hydrophone for measurement of high-amplitude therapeutic ultrasound fields; The Journal of the Acoustical Society of America, vol. 119, pp. 1432-1440, Mar. 2006.
Parsons et al.; Pulsed cavitational ultrasound therapy for controlled tissue homogenization; Ultrasound in Med. & Biol.; vol. 32(1); pp. 115-129; Jan. 2006.
Pishchalnikov et al.; Cavitation Bubble Cluster Activity in the Breakage of Kidney Stones by Lithotripter Shock Waves; J Endourol.; 17(7): 435-446; Sep. 2003.
Porter et al.; Reduction in left ventricular cavitary attenuation and improvement in posterior myocardial contrast . . .; J Am Soc Echocardiography; pp. 437-441; Jul.-Aug. 1996.
Roberts et al.; Pulsed cavitational ultrasound: a noninvasive technology for controlled tissue ablation (histotripsy) in the rabbit kidney; Journal of Urology; vol. 175(2); pp. 734-738; Feb. 2006.
Rosenschein et al.; Ultrasound Imaging-Guided Noninvasive Ultrasound Thrombolysis: Preclinical Results; Circulation; vol. 102; pp. 238-245, Jul. 11, 2000.
Rowland et al.; MRI study of hepatic tumours following high intensity focused ultrasound surgery; British Journal of Radiology; 70; pp. 144-153; Feb. 1997.
Roy et al.; A precise technique for the measurement of acoustic cavitation thresholds and some preliminary results; Journal of the Acoustical Society of America; vol. 78(5); pp. 1799-1805; Nov. 1985.
Sapareto et al.; Thermal dose determination in cancer therapy; Int J Radiat Oncol Biol Phys; 10(6); pp. 787-800; Apr. 1984.
Sapozhnikov et al.; Ultrasound-Guided Localized Detection of Cavitation During Lithotripsy in Pig Kidney in Vivo; IEEE Ultrasonics Symposium, vol. 2; pp. 1347-1350; Oct. 7-10, 2001.
Sato et al.; Experimental Investigation of Phased Array Using Tapered Matching Layers. 2002 IEEE Ultrasound Symposium. vol. 2; pp. 1235-1238, Oct. 2002.
Simonin et al.; Characterization of heterogeneous structure in a polymer object manufactured by stereolithography with low-frequency microechography; Journal of Materials Chemistry; vol. 6, pp. 1595-1599, Sep. 1996.
Sokolov et al.; Use of a dual-pulse lithotripter to generate a localized and intensified cavitation field; Journal of the Acoustical Society of America; vol. 110(3); pp. 1685-1695; Sep. 2001.
Song et al.; Feasibility of Using Lateral Mode Coupling Method for a Large Scale Ultrasound Phased Array for Noninvasive Transcranial Therapy; Biomedical Engineering; IEEE Transactions on, vol. 57, pp. 124-133; Jan. 2010 (author manuscript).
Souchon et al.; Visualisation of HIFU lesions using elastography of the human prostate in vivo: Preliminary results; Ultrasound Med. Biol; 29(7); pp. 1007-1015; Jul. 2003.
Souquet et al.; Design of Low-Loss Wide-Band Ultrasonic Transducers for Noninvasive Medical Application; Sonics and Ultrasonics, IEEE Transactions on, vol. 26, pp. 75-80, Mar. 1979.
Therapeutic Ultrasound Group. Non-invasive Ultrasonic Tissue Fraction for Treatment of Benign Disease and Cancer—“Histotripsy”. University research [online]. Biomedical Engineering Department, University of Michigan. Jul. 2011[retrieved on Jan. 28, 2014] from: (http://web.archive.org/web/20110720091822/http://www.histotripsy.umich.edu/index.html>.entiredocument) Jul. 2011.
Toda; Narrowband impedance matching layer for high efficiency thickness mode ultrasonic transducers; Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on, vol. 49, pp. 299-306, Mar. 2002.
Van Kervel et al.; A calculation scheme for the optimum design of ultrasonic transducers; Ultrasonics, vol. 21, pp. 134-140, May 1983.
Wang et al.; Quantitative ultrasound backscatter for pulsed cavitational ultrasound therapy-histotripsy; Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on, vol. 56, pp. 995-1005, May 2009.
Xie et al.; Correspondence of ultrasound elasticity imaging to direct mechanical measurement in aging DVT in rats; Ultrasound Med Biol; 31(10); pp. 1351-1359; Oct. 2005 (author manuscript, 20 pgs.).
Xu et al.; A new strategy to enhance cavitational tissue erosion by using a high intensity initiating sequence; IEEE Trans Ultrasonics Ferroelectrics and Freq Control; vol. 53(8); pp. 1412-1424; Aug. 2006.
Xu et al.; Controlled ultrasound tissue erosion: the role of dynamic interaction between insonation and microbubble activity; Journal of the Acoustical Society of America; vol. 117(1); pp. 424-435; Jan. 2005.
Xu et al.; Controlled ultrasound tissue erosion; IEEE Transaction on Ultrasonics, Ferroelectrics, and Frequency Control; vol. 51 (6); pp. 726-736; Jun. 2004.
Xu et al.; Effects of acoustic parameters on bubble cloud dynamics in ultrasound tissue erosion (histotripsy); Journal of the Acoustical Society of America; vol. 122(1); pp. 229-236; Jul. 2007.
Xu et al.; High Speed Imaging of Bubble Clouds Generated in Pulsed Ultrasound Cavitational Therapy'Histotripsy; IEEE Trans Ultrason Ferroelectr Freq Control; ; vol. 54; No. 10; pp. 2091R2101; Oct. 2007.
Xu et al.; Investigation of intensity threshold for ultrasound tissue erosion; Ultrasound in Med. & Biol.; vol. 31(12); pp. 1673-1682; Dec. 2005.
Xu et al.; Optical and acoustic monitoring of bubble cloud dynamics at a tissue-fluid interface in ultrasound tissue erosion; Journal of the Acoustical Society of America; vol. 121(4); pp. 2421-2430; Apr. 2007.
Yan et al.; A review of rapid prototyping technologies and systems; Computer-Aided Design, vol. 28, pp. 307-318, Apr. 1996.
Zhang et al.; A fast tissue stiffness-dependent elastography for HIFU-induced lesions inspection; Ultrasonics; 51(8); pp. 857-869; Dec. 2011.
Zheng et al.; An acoustic backscatter-based method for localization of lesions induced by high-intensity focused ultrasound; Ultrasound Med Biol; 36(4); pp. 610-622; Apr. 2010.
Rakic et al.; U.S. Appl. No. 14/899,139 entitled “Articulating arm limiter for cavitational ultrasound therapy system,” filed Dec. 17, 2015.
Hall et al.; U.S. Appl. No. 15/583,852 entitled “Method of manufacturing an ultrasound system,” filed May 1, 2017.
Cannata et al.; U.S. Appl. No. 16/698,587 entitled “Histotripsy systems and methods,” filed Nov. 27, 2019.
Related Publications (1)
Number Date Country
20160184616 A1 Jun 2016 US
Provisional Applications (1)
Number Date Country
61868992 Aug 2013 US